Symbols / CODX
CODX Chart
About
Co-Diagnostics, Inc. operates as a molecular diagnostics company that develops, manufactures, and sells reagents used for diagnostic tests that function through the detection and/or analysis of nucleic acid molecules in the United States and internationally. The company offers Co-Dx PCR platform, a polymerase chain reaction testing to patients in point-of-care and at-home setting. It also provides PCR diagnostic tests for COVID-19, influenza, tuberculosis, hepatitis B and C, human papillomavirus, malaria, chikungunya, dengue, and the zika virus. In addition, the company offers three multiplexed tests to test mosquitos for the identification of diseases carried by the mosquitos; molecular tools for detection of infectious diseases, liquid biopsy for cancer screening, and agricultural applications; tests that identify genetic traits in plant and animal genomes; and portable diagnostic device designed to bring PCR to patients in point-of-care and at-home settings. The company was incorporated in 2013 and is based in Salt Lake City, Utah.
Fundamentals
Scroll to Statements| Sector | Healthcare | Industry | Medical Devices | Market Cap | 4.61M |
| Enterprise Value | -5.23M | Income | -32.18M | Sales | 507.89K |
| Book/sh | 24.82 | Cash/sh | 5.64 | Dividend Yield | — |
| Payout | 0.00% | Employees | 132 | IPO | — |
| P/E | — | Forward P/E | -0.18 | PEG | — |
| P/S | 9.07 | P/B | 0.09 | P/C | — |
| EV/EBITDA | 0.15 | EV/Sales | -10.31 | Quick Ratio | 3.36 |
| Current Ratio | 3.81 | Debt/Eq | 3.70 | LT Debt/Eq | — |
| EPS (ttm) | -29.40 | EPS next Y | -12.15 | EPS Growth | — |
| Revenue Growth | -77.30% | Earnings | 2026-03-31 | ROA | -37.92% |
| ROE | -62.12% | ROIC | — | Gross Margin | 34.03% |
| Oper. Margin | -48.24% | Profit Margin | 0.00% | Shs Outstand | 2.10M |
| Shs Float | 1.94M | Short Float | 3.90% | Short Ratio | 1.19 |
| Short Interest | — | 52W High | 46.50 | 52W Low | 2.16 |
| Beta | 1.32 | Avg Volume | 70.80K | Volume | 1.24K |
| Target Price | — | Recom | None | Prev Close | $2.32 |
| Price | $2.20 | Change | -5.17% |
Valuation Models
Price estimates from analyst targets and simple models.
1. Analyst consensus
—
Mean price target
2. Current target
$2.20
Latest analyst target
3. DCF / Fair value
$-176.13
Simplified: (Free Cash Flow ÷ Shares) × 18 (P/FCF multiple). Not a …
Ratings
Current target
$2.20
Low
—
High
—
Mean
—
Latest analyst rating changes
| Date | Action | Analyst | Rating Change | Price Target |
|---|---|---|---|---|
| 2025-11-26 | init | Maxim Group | — → Buy | $2 |
| 2025-11-24 | reit | HC Wainwright & Co. | Neutral → Neutral | — |
| 2025-10-28 | main | D. Boral Capital | Buy → Buy | $3 |
| 2025-10-16 | main | D. Boral Capital | Buy → Buy | $3 |
| 2025-09-19 | main | D. Boral Capital | Buy → Buy | $3 |
| 2025-09-17 | main | D. Boral Capital | Buy → Buy | $10 |
| 2025-08-15 | main | D. Boral Capital | Buy → Buy | $10 |
| 2025-04-28 | init | D. Boral Capital | — → Buy | $10 |
| 2025-03-28 | main | HC Wainwright & Co. | Neutral → Neutral | $1 |
| 2024-11-11 | reit | HC Wainwright & Co. | Neutral → Neutral | $2 |
| 2024-08-12 | main | HC Wainwright & Co. | Neutral → Neutral | $2 |
| 2024-06-17 | reit | HC Wainwright & Co. | Neutral → Neutral | $2 |
| 2024-05-13 | main | HC Wainwright & Co. | Neutral → Neutral | $2 |
| 2024-03-15 | main | HC Wainwright & Co. | Neutral → Neutral | $3 |
| 2023-12-29 | reit | HC Wainwright & Co. | Neutral → Neutral | $3 |
| 2023-11-13 | main | HC Wainwright & Co. | Neutral → Neutral | $3 |
| 2023-08-14 | main | HC Wainwright & Co. | Neutral → Neutral | $2 |
| 2023-05-15 | reit | HC Wainwright & Co. | Neutral → Neutral | $3 |
| 2023-03-20 | down | HC Wainwright & Co. | Buy → Neutral | $3 |
| 2023-02-23 | reit | HC Wainwright & Co. | — → Buy | $6 |
- Co-Diagnostics Announces Reverse Stock Split - PR Newswire ue, 30 Dec 2025 08
- India JV wins ISO seal to build cheaper Co-Dx home PCR devices - Stock Titan Wed, 04 Feb 2026 08
- CODX Shares Dip Despite Australian Patent Grant for Co-Dx PCR Platform - Yahoo Finance Wed, 31 Dec 2025 08
- Co-Diagnostics to be delisted from Nasdaq, trading to move to OTC Market - Investing.com ue, 13 Jan 2026 08
- Can Co-Diagnostics Stock Recover If Markets Fall? - Trefis Sun, 21 Dec 2025 08
- Co-Diagnostics (CODX) Price Target Increased by 2,900.00% to 38.25 - Nasdaq Wed, 14 Jan 2026 08
- Co-Diagnostics, Inc. (CODX) Reports Q3 Loss, Misses Revenue Estimates - Yahoo Finance hu, 13 Nov 2025 08
- Co-Diagnostics stock plummets after announcing $7 million offering - Investing.com ue, 28 Oct 2025 07
- Co-Diagnostics to Showcase PCR Platform at World Health Expo Labs Dubai - PR Newswire Mon, 09 Feb 2026 08
- Co-Diagnostics (NASDAQ: CODX) sets Nov 13 earnings release; 4:30 p.m. ET call - Stock Titan Fri, 31 Oct 2025 07
- Co-Diagnostics, Inc. Announces Pricing of $7.0 Million Registered Direct Offering of Common Stock Priced At-The-Market Under Nasdaq Rules - PR Newswire ue, 28 Oct 2025 07
- Inside Dubai's World Health Expo, Co-Diagnostics meets MENA lab leaders - Stock Titan Mon, 09 Feb 2026 08
- Co-Diagnostics JV CoSara Participates in Regional Conferences to Grow and Strengthen Distributor Relationships - PR Newswire Mon, 12 Jan 2026 08
- Co-Diagnostics Reports Third Quarter 2025 Financial Results - PR Newswire hu, 13 Nov 2025 08
- Co-Diagnostics, Inc. Announces Closing of $3.8 Million Registered Direct Offering of Common Stock Priced At-The-Market Under Nasdaq Rules - PR Newswire hu, 18 Sep 2025 07
Insider Transactions
| Date | Shares | Url | Text | Insider | Position | Transaction | Start Date | Ownership | Value |
|---|---|---|---|---|---|---|---|---|---|
| 0 | 57499 | — | — | SERBIN RICHARD S | Director | — | 2025-11-21 00:00:00 | D | nan |
| 1 | 163333 | — | — | EGAN DWIGHT H. | Chief Executive Officer | — | 2025-11-21 00:00:00 | D | nan |
| 2 | 57499 | — | — | NELSON JAMES B | Director | — | 2025-11-21 00:00:00 | D | nan |
| 3 | 57499 | — | — | MURPHY EDWARD L. | Director | — | 2025-11-21 00:00:00 | D | nan |
| 4 | 57499 | — | — | DURENARD EUGENE A | Director | — | 2025-11-21 00:00:00 | D | nan |
| 5 | 134167 | — | — | BROWN BRIAN LEE | Chief Financial Officer | — | 2025-11-21 00:00:00 | D | nan |
| 6 | 56667 | — | — | ABBOTT RICHARD DAVID | President | — | 2025-11-21 00:00:00 | D | nan |
| 7 | 575833 | — | — | EGAN DWIGHT H. | Chief Executive Officer | — | 2025-11-21 00:00:00 | D | nan |
| 8 | 228333 | — | — | NELSON JAMES B | Director | — | 2025-11-21 00:00:00 | D | nan |
| 9 | 228333 | — | — | MURPHY EDWARD L. | Director | — | 2025-11-21 00:00:00 | D | nan |
Financials
| Line Item | 2024-12-31 | 2023-12-31 | 2022-12-31 | 2021-12-31 |
|---|---|---|---|---|
| TaxEffectOfUnusualItems | 334.72K | 243.31K | -1.87M | -8.74K |
| TaxRateForCalcs | 0.21 | 0.07 | 0.24 | 0.20 |
| NormalizedEBITDA | -40.30M | -44.81M | -2.68M | 46.44M |
| TotalUnusualItems | 1.59M | 3.33M | -7.63M | -44.35K |
| TotalUnusualItemsExcludingGoodwill | 1.59M | 3.33M | -7.63M | -44.35K |
| NetIncomeFromContinuingOperationNetMinorityInterest | -37.64M | -35.33M | -14.24M | 36.66M |
| ReconciledDepreciation | 1.38M | 1.23M | 1.28M | 335.36K |
| ReconciledCostOfRevenue | 999.12K | 4.18M | 5.48M | 11.57M |
| EBITDA | -38.70M | -41.48M | -10.31M | 46.40M |
| EBIT | -40.08M | -42.71M | -11.59M | 46.06M |
| NetInterestIncome | 1.09M | 1.16M | 704.04K | 45.63K |
| InterestIncome | 1.09M | 1.16M | 704.04K | 45.63K |
| NormalizedIncome | -38.90M | -38.42M | -8.48M | 36.69M |
| NetIncomeFromContinuingAndDiscontinuedOperation | -37.64M | -35.33M | -14.24M | 36.66M |
| TotalExpenses | 44.00M | 49.52M | 45.81M | 51.82M |
| TotalOperatingIncomeAsReported | -40.08M | -42.71M | -26.98M | 46.06M |
| DilutedAverageShares | 1.01M | 978.22K | 1.05M | 996.79K |
| BasicAverageShares | 1.01M | 978.22K | 1.05M | 962.49K |
| DilutedEPS | -37.20 | -36.00 | -13.50 | 36.90 |
| BasicEPS | -37.20 | -36.00 | -13.50 | 38.10 |
| DilutedNIAvailtoComStockholders | -37.64M | -35.33M | -14.24M | 36.66M |
| NetIncomeCommonStockholders | -37.64M | -35.33M | -14.24M | 36.66M |
| NetIncome | -37.64M | -35.33M | -14.24M | 36.66M |
| NetIncomeIncludingNoncontrollingInterests | -37.64M | -35.33M | -14.24M | 36.66M |
| NetIncomeContinuousOperations | -37.64M | -35.33M | -14.24M | 36.66M |
| TaxProvision | 57.37K | -2.78M | -4.61M | 8.98M |
| PretaxIncome | -37.58M | -38.11M | -18.85M | 45.64M |
| OtherIncomeExpense | 1.41M | 3.43M | -7.96M | -474.79K |
| SpecialIncomeCharges | 723.17K | 1.09M | -7.63M | -44.35K |
| GainOnSaleOfPPE | 8.29K | -2.58K | -138.12K | -44.35K |
| ImpairmentOfCapitalAssets | 0.00 | 15.39M | 0.00 | |
| RestructuringAndMergernAcquisition | -714.88K | -1.09M | -7.90M | 0.00 |
| EarningsFromEquityInterest | -186.07K | 100.70K | -332.97K | -430.43K |
| GainOnSaleOfSecurity | 870.75K | 2.24M | ||
| NetNonOperatingInterestIncomeExpense | 1.09M | 1.16M | 704.04K | 45.63K |
| InterestIncomeNonOperating | 1.09M | 1.16M | 704.04K | 45.63K |
| OperatingIncome | -40.08M | -42.71M | -11.59M | 46.06M |
| OperatingExpense | 43.00M | 45.33M | 40.33M | 40.25M |
| DepreciationAmortizationDepletionIncomeStatement | 1.38M | 1.23M | 1.28M | 335.36K |
| DepreciationAndAmortizationInIncomeStatement | 1.38M | 1.23M | 1.28M | 335.36K |
| ResearchAndDevelopment | 20.98M | 22.96M | 17.44M | 14.96M |
| SellingGeneralAndAdministration | 20.64M | 21.14M | 21.61M | 24.95M |
| SellingAndMarketingExpense | 4.48M | 6.86M | 7.34M | 13.40M |
| GeneralAndAdministrativeExpense | 16.16M | 14.28M | 14.26M | 11.55M |
| OtherGandA | 16.16M | 14.28M | 14.26M | 11.55M |
| GrossProfit | 2.92M | 2.63M | 28.74M | 86.31M |
| CostOfRevenue | 999.12K | 4.18M | 5.48M | 11.57M |
| TotalRevenue | 3.92M | 6.81M | 34.22M | 97.89M |
| OperatingRevenue | 3.92M | 6.81M | 34.22M | 97.89M |
| Line Item | 2024-12-31 | 2023-12-31 | 2022-12-31 | |
|---|---|---|---|---|
| TreasurySharesNumber | 161.62K | 161.62K | 129.39K | |
| OrdinarySharesNumber | 1.10M | 1.04M | 1.03M | 1.13M |
| ShareIssued | 1.26M | 1.20M | 1.16M | 1.13M |
| TotalDebt | 2.15M | 2.99M | 347.92K | 0.00 |
| TangibleBookValue | 28.21M | 59.61M | 87.75M | 92.57M |
| InvestedCapital | 54.31M | 86.01M | 114.52M | 134.48M |
| WorkingCapital | 24.98M | 56.39M | 88.86M | 102.52M |
| NetTangibleAssets | 28.21M | 59.61M | 87.75M | 92.57M |
| CapitalLeaseObligations | 2.15M | 2.99M | 347.92K | 0.00 |
| CommonStockEquity | 54.31M | 86.01M | 114.52M | 134.48M |
| TotalCapitalization | 54.31M | 86.01M | 114.52M | 134.48M |
| TotalEquityGrossMinorityInterest | 54.31M | 86.01M | 114.52M | 134.48M |
| StockholdersEquity | 54.31M | 86.01M | 114.52M | 134.48M |
| GainsLossesNotAffectingRetainedEarnings | 418.44K | 146.70K | 293.14K | 0.00 |
| OtherEquityAdjustments | 418.44K | 146.70K | 293.14K | |
| TreasuryStock | 15.58M | 15.58M | 14.21M | 0.00 |
| RetainedEarnings | -33.04M | 4.60M | 39.93M | 54.17M |
| AdditionalPaidInCapital | 102.47M | 96.81M | 88.47M | 80.27M |
| CapitalStock | 37.90K | 36.11K | 34.75K | 33.82K |
| CommonStock | 37.90K | 36.11K | 34.75K | 33.82K |
| PreferredStock | 0.00 | 0.00 | 0.00 | 0.00 |
| TotalLiabilitiesNetMinorityInterest | 9.69M | 9.31M | 8.57M | 25.56M |
| TotalNonCurrentLiabilitiesNetMinorityInterest | 2.37M | 3.56M | 4.69M | 12.96M |
| OtherNonCurrentLiabilities | 422.08K | 748.11K | 1.04M | 4.67M |
| NonCurrentAccruedExpenses | 0.00 | |||
| TradeandOtherPayablesNonCurrent | 713.64K | 659.19K | 1.18M | 1.07M |
| NonCurrentDeferredLiabilities | 0.00 | 2.42M | 7.23M | |
| NonCurrentDeferredTaxesLiabilities | 0.00 | 2.42M | 7.23M | |
| LongTermDebtAndCapitalLeaseObligation | 1.24M | 2.15M | 50.71K | 0.00 |
| LongTermCapitalLeaseObligation | 1.24M | 2.15M | 50.71K | 0.00 |
| CurrentLiabilities | 7.32M | 5.75M | 3.87M | 12.60M |
| OtherCurrentLiabilities | 502.82K | 891.67K | 1.69M | 5.77M |
| CurrentDeferredLiabilities | 40.86K | 362.45K | 0.00 | 150.00K |
| CurrentDeferredRevenue | 40.86K | 362.45K | 0.00 | 150.00K |
| CurrentDebtAndCapitalLeaseObligation | 915.62K | 838.39K | 297.21K | |
| CurrentCapitalLeaseObligation | 915.62K | 838.39K | 297.21K | 0.00 |
| PayablesAndAccruedExpenses | 5.86M | 3.66M | 1.89M | 6.68M |
| CurrentAccruedExpenses | 2.56M | 2.17M | 934.45K | 3.86M |
| Payables | 3.29M | 1.48M | 952.30K | 2.82M |
| TotalTaxPayable | 0.00 | 2.21M | ||
| IncomeTaxPayable | 0.00 | 2.21M | ||
| AccountsPayable | 3.29M | 1.48M | 952.30K | 607.51K |
| TotalAssets | 64.00M | 95.32M | 123.09M | 160.03M |
| TotalNonCurrentAssets | 31.71M | 33.18M | 30.35M | 44.91M |
| NonCurrentDeferredAssets | 0.00 | |||
| NonCurrentDeferredTaxesAssets | 0.00 | |||
| NonCurrentNoteReceivables | 0.00 | 75.00K | ||
| InvestmentsAndAdvances | 731.07K | 773.38K | 672.68K | 1.00M |
| LongTermEquityInvestment | 731.07K | 773.38K | 672.68K | 1.00M |
| InvestmentsinJointVenturesatCost | 731.07K | 773.38K | 672.68K | 1.00M |
| GoodwillAndOtherIntangibleAssets | 26.10M | 26.40M | 26.77M | 41.90M |
| OtherIntangibleAssets | 26.10M | 26.40M | 26.77M | 27.20M |
| Goodwill | 0.00 | 14.71M | ||
| NetPPE | 4.88M | 6.00M | 2.91M | 1.93M |
| AccumulatedDepreciation | -3.28M | -2.23M | -1.37M | -622.15K |
| GrossPPE | 8.16M | 8.23M | 4.28M | 2.56M |
| Leases | 947.67K | 548.65K | 224.96K | 3.16K |
| OtherProperties | 7.04M | 7.51M | 3.95M | 2.48M |
| MachineryFurnitureEquipment | 173.67K | 173.67K | 112.04K | 75.40K |
| Properties | 0.00 | 0.00 | 0.00 | 0.00 |
| CurrentAssets | 32.29M | 62.14M | 92.73M | 115.12M |
| OtherCurrentAssets | 1.34M | 1.60M | 761.19K | 2.34M |
| PrepaidAssets | 2.34M | |||
| Inventory | 1.07M | 1.66M | 5.31M | 2.00M |
| FinishedGoods | 567.28K | 700.47K | 1.33M | 983.09K |
| RawMaterials | 505.44K | 964.26K | 3.98M | 1.02M |
| Receivables | 132.57K | 330.88K | 5.40M | 20.91M |
| TaxesReceivable | 0.00 | 26.95K | 1.87M | 0.00 |
| NotesReceivable | 0.00 | 75.00K | 75.00K | |
| AccountsReceivable | 132.57K | 303.93K | 3.45M | 20.84M |
| AllowanceForDoubtfulAccountsReceivable | -110.06K | -200.34K | -3.10M | -669.60K |
| GrossAccountsReceivable | 242.62K | 504.26K | 6.55M | 21.51M |
| CashCashEquivalentsAndShortTermInvestments | 29.75M | 58.55M | 81.26M | 89.86M |
| OtherShortTermInvestments | 26.81M | 43.63M | 58.29M | 1.26M |
| CashAndCashEquivalents | 2.94M | 14.92M | 22.97M | 88.61M |
| CashEquivalents | 0.00 | 10.60M | 10.14M | |
| CashFinancial | 2.94M | 4.32M | 12.83M |
| Line Item | 2024-12-31 | 2023-12-31 | 2022-12-31 | 2021-12-31 |
|---|---|---|---|---|
| FreeCashFlow | -29.90M | -23.45M | 5.14M | 40.41M |
| RepurchaseOfCapitalStock | 0.00 | -1.36M | -14.21M | 0.00 |
| IssuanceOfCapitalStock | 103.91K | 0.00 | 0.00 | |
| CapitalExpenditure | -748.35K | -1.37M | -1.43M | -669.46K |
| InterestPaidSupplementalData | 0.00 | 0.00 | 0.00 | |
| IncomeTaxPaidSupplementalData | 0.00 | 55.98K | 4.50M | 5.40M |
| EndCashPosition | 2.94M | 14.92M | 22.97M | 88.61M |
| BeginningCashPosition | 14.92M | 22.97M | 88.61M | 42.98M |
| ChangesInCash | -11.98M | -8.06M | -65.63M | 45.63M |
| FinancingCashFlow | 103.91K | -1.36M | -14.03M | 450.40K |
| CashFlowFromContinuingFinancingActivities | 103.91K | -1.36M | -14.03M | 450.40K |
| ProceedsFromStockOptionExercised | 0.00 | 177.87K | 450.40K | |
| NetCommonStockIssuance | 103.91K | -1.36M | -14.21M | 0.00 |
| CommonStockPayments | 0.00 | -1.36M | -14.21M | 0.00 |
| CommonStockIssuance | 103.91K | 0.00 | 0.00 | |
| InvestingCashFlow | 17.07M | 15.39M | -58.17M | 4.10M |
| CashFlowFromContinuingInvestingActivities | 17.07M | 15.39M | -58.17M | 4.10M |
| NetInvestmentPurchaseAndSale | 17.96M | 16.75M | -56.74M | 3.08M |
| SaleOfInvestment | 58.77M | 127.25M | 11.26M | 3.08M |
| PurchaseOfInvestment | -40.80M | -110.50M | -68.00M | 0.00 |
| NetBusinessPurchaseAndSale | -143.75K | 0.00 | 0.00 | 1.69M |
| SaleOfBusiness | 0.00 | 1.69M | ||
| PurchaseOfBusiness | -143.75K | 0.00 | ||
| NetPPEPurchaseAndSale | -748.35K | -1.37M | -1.43M | -669.46K |
| PurchaseOfPPE | -748.35K | -1.37M | -1.43M | -669.46K |
| OperatingCashFlow | -29.16M | -22.08M | 6.57M | 41.08M |
| CashFlowFromContinuingOperatingActivities | -29.16M | -22.08M | 6.57M | 41.08M |
| ChangeInWorkingCapital | 2.75M | 5.64M | 6.19M | -2.90M |
| ChangeInOtherWorkingCapital | -321.59K | 362.45K | -150.00K | -155.31K |
| ChangeInPayablesAndAccruedExpense | 2.21M | 1.25M | -4.69M | 2.34M |
| ChangeInPayable | 2.21M | 1.25M | -4.69M | 2.34M |
| ChangeInAccountPayable | 2.16M | 1.77M | -2.48M | -299.94K |
| ChangeInTaxPayable | 54.46K | -522.10K | -2.20M | 2.64M |
| ChangeInIncomeTaxPayable | 54.46K | -522.10K | -2.20M | 2.64M |
| ChangeInPrepaidAssets | 412.06K | 1.08M | -224.09K | -2.05M |
| ChangeInInventory | 265.49K | 413.14K | -3.67M | 5.71M |
| ChangeInReceivables | 186.39K | 2.54M | 14.92M | -8.74M |
| ChangesInAccountReceivables | 186.39K | 2.54M | 14.92M | -8.74M |
| OtherNonCashItems | -701.37K | -3.46M | -12.68M | 930.08K |
| StockBasedCompensation | 5.43M | 8.34M | 7.54M | 5.51M |
| ProvisionandWriteOffofAssets | -15.04K | 612.81K | 2.46M | |
| AssetImpairmentCharge | 326.51K | 3.23M | 15.54M | 69.67K |
| DeferredTax | 0.00 | -2.42M | -4.81M | 930.08K |
| DeferredIncomeTax | 0.00 | -2.42M | -4.81M | 930.08K |
| DepreciationAmortizationDepletion | 1.38M | 1.23M | 1.28M | 335.36K |
| DepreciationAndAmortization | 1.38M | 1.23M | 1.28M | 335.36K |
| OperatingGainsLosses | -692.97K | -2.34M | 471.09K | 474.79K |
| EarningsLossesFromEquityInvestments | 186.07K | -100.70K | 332.97K | 430.43K |
| GainLossOnInvestmentSecurities | -870.75K | -2.24M | ||
| NetIncomeFromContinuingOperations | -37.64M | -35.33M | -14.24M | 36.66M |
SEC Filings
Recent 10-K, 10-Q, 8-K, and Form 4 (insider) filings.
Public Trades for CODX
| Date | User | Asset | Broker | Type | Position Size | Entry Price | Patterns |
|---|